(R)-4-(2-羟乙基)-2,2-二甲基-1,3-二氧戊环 | 70005-89-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (R)-4-(2-羟乙基)-2,2-二甲基-1,3-二氧戊环
• 中文别名: (R)-4-(2-羟乙基)-2,2-二甲基-1,3-二恶烷；(R)-4-(2-羟基乙基)-2,2-二甲基-1,3-二氧戊环；(4R)-4-(2-羟基乙基)-2,2-二甲基-1,3-二氧戊环；(4R)-4-(2-羟乙基)-2,2-二甲基-1,3-二氧戊环
• 英文名称: 2-((4R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethanol
• 英文别名: (R)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol；(4R)-4-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolane；(R)-2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethanol；2-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethanol；2-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol
• CAS: 70005-89-9
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: YYEZYENJAMOWHW-ZCFIWIBFSA-N

物化性质

• 沸点：
  207 °C(lit.)
• 密度：
  1.045 g/mL at 25 °C(lit.)
• 闪点：
  224 °F

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2932999099
• 安全说明：
  S26,S36
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  (R)-4-(2-羟乙基)-2,2-二甲基-1,3-二氧戊环 在 indium(III) triflate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.08h， 以99%的产率得到(R)-(+)-1,2,4-丁三醇
  参考文献：
  名称：

  Mild, versatile, and chemoselective indium(III) triflate-catalyzed deprotection of acetonides under microwave heating conditions

  摘要：

  A series of acetonides (both terminal and internal isopropylidene acetals) have been deprotected under catalytic, neutral conditions to give their corresponding 1,2-diols. The reactions utilize indium(III) triflate in the presence of water and an organic solvent with mild microwave heating. Terminal acetonides are chemoselectivley removed in the presence of internal acetonides; acid labile functional groups remain intact under these conditions, thereby greatly enhancing the scope of the reaction substrates that can be utilized with this approach. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.05.116
• 作为产物：
  描述：

  (R)-2,2-二甲基-1,3-二氧戊环-4-乙酸甲酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 (R)-4-(2-羟乙基)-2,2-二甲基-1,3-二氧戊环
  参考文献：
  名称：

  Preparation of Derivtives of (R)-1,2,4-Butanetriol from L-Ascorbic Acid

  摘要：

  从 L-抗坏血酸中得到的 3,4-O-异亚丙基 L-苏氨酸甲酯（3）被转化为其 O-苯基硫代碳酸酯 4。用氢化三正丁基锡对 4 进行脱氧反应，得到受保护的 3,4-二羟基丁酸酯 5，再将其转化为 (R)-1,2,4-丁三醇衍生物 6 和 7。

  DOI：

  10.1055/s-1988-27521

文献信息

• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• Asymmetric 1,3-Dipolar Cycloaddition of Nitrones with an Electron-Withdrawing Group to Allylic Alcohols Utilizing Diisopropyl Tartrate as a Chiral Auxiliary
  作者：Xia Ding、Katsumi Taniguchi、Yoshihira Hamamoto、Kazunori Sada、Shuhei Fujinami、Yutaka Ukaji、Katsuhiko Inomata

  DOI：10.1246/bcsj.79.1069

  日期：2006.7

  The asymmetric 1,3-dipolar cycloaddition of nitrones possessing an electron-withdrawing group to allylic alcohols was achieved by the use of diisopropyl (R,R)-tartrate as a chiral auxiliary to afford the corresponding isoxazolidines with high regio-, diastereo-, and enantioselectivity. In the case of nitrones possessing an electron-withdrawing cyano or t-butoxycarbonyl group, 1,3-dipolar cycloaddition

  具有吸电子基团的硝酮与烯丙醇的不对称 1,3-偶极环加成反应是通过使用酒石酸二异丙酯作为手性助剂来实现的，得到相应的异恶唑烷，具有高区域-、非对映-、和对映选择性。在硝酮具有吸电子氰基或叔丁氧基羰基的情况下，1,3-偶极环加成与 2-丙烯-1-醇发生产生相应的具有高对映选择性的 3,5-反式异恶唑烷。相反，具有酰胺部分的硝酮提供了相应的光学活性 3,5-顺式异恶唑烷，具有完全相反的非对映选择性。具有 N 的硝酮的催化不对称 1,3-偶极环加成，N-二异丙基酰胺部分转化为烯丙醇，得到二或三取代的异恶唑烷，对映选择性高达 99% 以上。本不对称 1,3-偶极环加成应用于 (2S,4R)-4-羟基鸟氨酸衍生物的合成。
• Benzimidazole compound
  申请人：Miyazawa Shuhei

  公开号：US20070010542A1

  公开（公告）日：2007-01-11

  An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where R 1 and R 3 may be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; R 2 represents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R 4 , R 5 , R 6 and R 7 represent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and W 1 represents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.

  本发明的目的是提供一种新型化合物，可用作治疗或预防酸相关疾病的药物，具有出色的抑制胃酸分泌作用，保持抑制胃酸分泌作用的出色效果，从而长时间保持胃内pH值高，并具有更高的安全性和适当的理化稳定性。 提供的化合物表示为 其中R 1 和R 3 可以相同也可以不同，每个代表氢原子或C1-C6烷基；R 2 表示(5,5-二甲基-1,3-二氧杂环戊烷-2-基)甲氧基基团，5,7-二氧杂螺[2.5]辛-6-基甲氧基基团，1,5,9-三氧杂螺[5.5]十一烷-3-基甲氧基基团，或(2,2-二甲基-1,3-二氧杂环戊烷-5-基)甲氧基基团； R 4 ，R 5 ，R 6 和R 7 代表氢原子，卤原子，C1-C6烷基，C1-C6卤代烷基，C1-C6烷氧基或C1-C6卤代烷氧基；W 1 表示单键，亚甲基或乙烯基，其盐或这些的溶剂化合物。
• Substituted Pyrrolidine-2-Carboxamides
  申请人：Ding Qingjie

  公开号：US20100075948A1

  公开（公告）日：2010-03-25

  There are provided compounds of the formula wherein X, Y, R 1 , R 2 , R 3 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式的化合物 其中X、Y、R1、R2、R3、R3、R4、R5、R6和R7如本文所述，以及其对映体和药用可接受的盐和酯。这些化合物可用作抗癌药物。
• NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP3305789A1

  公开（公告）日：2018-04-11

  The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3A R3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.

  本发明提供了一种具有抗病毒活性的新型化合物，特别是具有抑制HIV复制活性的化合物和含有该化合物的药物。该化合物由以下式表示： 其中A3为CR3A、CR3A R3B、N或NR3C；R3A、R3B、R4A和R4B分别独立地为氢原子、卤素、氰基、取代或未取代的烷基、取代或未取代的炔基，或取代或未取代的非芳香碳环烷基；R3C为氢原子、取代或未取代的烷基，或取代或未取代的非芳香碳环烷基；环T1为取代或未取代的含氮非芳香杂环；R1为氢原子、卤素、氰基，或取代或未取代的烷基；R2分别为取代或未取代的烷基或类似物；n为1或2；R3为取代或未取代的芳香碳环烷基或类似物；R4为氢原子或羧基保护基。